Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
Authors:
- Young Chan KimYKYoung Chan Kim
- Cesar Lopez-CamachoCLCesar Lopez-Camacho
- Joanne E. NettleshipJNJoanne E. Nettleship
- Nahid RahmanNRNahid Rahman
- Michelle L. HillMHMichelle L. Hill
- Laura Silva-ReyesLSLaura Silva-Reyes
- Georgina Ortiz-MartinezGOGeorgina Ortiz-Martinez
- Gloria Figueroa-AguilarGFGloria Figueroa-Aguilar
- María Antonieta MarMMMaría Antonieta Mar
- Héctor Vivanco-CidHVHéctor Vivanco-Cid
- Christine S. RollierChristine S. Rollier
- Nicole ZitzmannNZNicole Zitzmann
Open Access
- 27 December 2018
- journal article
- research article
- Published by Springer Nature in Virology Journal
- Vol. 15 (1) , 1-12
Abstract
Zika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based on the African lineage and produced in insect cells. Here, we sought to produce Asian-lineage ZIKV Env in mammalian cells for research and clinical applications. We designed various gene expression constructs to optimize the production of ZIKV using prM-Env and full or C-terminal truncations of Env; with or without a rat CD4 fusion partner to allow large-scale production of soluble protein in mammalian HEK293 cells. Protein expression was verified by mass spectrometry and western-blot with a pan-flavivirus antibody, a ZIKV Env monoclonal antibody and with immune sera from adenoviral (ChAdOx1) ZIKV Env-vaccinated mice. The resulting Env-CD4 was used as a coating reagent for immunoassay (ELISA) using both mouse and human seropositive sera. Replacement of the C-terminus transmembrane Env domain by a rat CD4 and addition of prM supported optimal expression and secretion of Env. Binding between the antigens and the antibodies was similar to binding when using commercially available ZIKV Env reagents. Furthermore, antibodies from ZIKV patients bound ZIKV Env-CD4 in ELISA assays, whereas sera from healthy blood donors yielded minimal OD background. The serological outcomes of this assay correlated also with ZIKV neutralisation capacity in vitro. Results obtained from this study indicate the potential of the Asian-lineage Zika Env-CD4 and Env proteins in ELISA assays to monitor humoral immune responses in upcoming clinical trials as well as a sero-diagnostic tool in ZIKV infection.Keywords
Funding Information
- Innovate UK (972216)
This publication has 46 references indexed in Scilit:
- Quantitative real-time PCR detection of Zika virus and evaluation with field-caught MosquitoesVirology Journal, 2013
- Review of diagnostic plaque reduction neutralization tests for flavivirus infectionThe Veterinary Journal, 2013
- Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRINature Structural & Molecular Biology, 2011
- Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue VirusesViral Immunology, 2008
- The Flavivirus Precursor Membrane-Envelope Protein Complex: Structure and MaturationScience, 2008
- A versatile ligation-independent cloning method suitable for high-throughput expression screening applicationsNucleic Acids Research, 2007
- Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika virusesArchives of Virology, 2007
- Solution Structure and Structural Dynamics of Envelope Protein Domain III of Mosquito- and Tick-Borne FlavivirusesBiochemistry, 2004
- Folding and Dimerization of Tick-Borne Encephalitis Virus Envelope Proteins prM and E in the Endoplasmic ReticulumJournal of Virology, 2002
- FLAVIVIRUS GENOME ORGANIZATION, EXPRESSION, AND REPLICATIONAnnual Review of Microbiology, 1990